Published in TB and Outbreaks Week, February 20th, 2007
VioQuest has executed a Cooperative Research and Development Agreement (CRADA) with the U.S. Army relating to VQD-001's development and regulatory filing process for a new drug application (NDA) for the treatment of cutaneous leishmaniasis. VioQuest plans to submit an NDA to the FDA for VQD-001 this year based on trial data from clinical studies conducted...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.